JP2010213710A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010213710A5 JP2010213710A5 JP2010101148A JP2010101148A JP2010213710A5 JP 2010213710 A5 JP2010213710 A5 JP 2010213710A5 JP 2010101148 A JP2010101148 A JP 2010101148A JP 2010101148 A JP2010101148 A JP 2010101148A JP 2010213710 A5 JP2010213710 A5 JP 2010213710A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- seq
- administered
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB02116259XA CN1219882C (zh) | 2002-03-18 | 2002-03-26 | 以erbb－3为基础的用于肿瘤治疗的方法和组合物 |
| CN02116259.X | 2002-03-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003578561A Division JP4660094B2 (ja) | 2002-03-26 | 2003-03-26 | 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010213710A JP2010213710A (ja) | 2010-09-30 |
| JP2010213710A5 true JP2010213710A5 (enExample) | 2011-06-16 |
| JP5249282B2 JP5249282B2 (ja) | 2013-07-31 |
Family
ID=28048642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003578561A Expired - Fee Related JP4660094B2 (ja) | 2002-03-26 | 2003-03-26 | 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 |
| JP2010101148A Expired - Lifetime JP5249282B2 (ja) | 2002-03-26 | 2010-04-26 | 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003578561A Expired - Fee Related JP4660094B2 (ja) | 2002-03-26 | 2003-03-26 | 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7919098B2 (enExample) |
| EP (2) | EP2400021B1 (enExample) |
| JP (2) | JP4660094B2 (enExample) |
| CN (1) | CN100424175C (enExample) |
| AU (1) | AU2003218600C1 (enExample) |
| CA (1) | CA2480099C (enExample) |
| WO (1) | WO2003080835A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| CN101594877A (zh) * | 2005-11-02 | 2009-12-02 | 杜克大学 | 同时的化学疗法和免疫疗法 |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| ES2530526T3 (es) | 2005-12-30 | 2015-03-03 | Zensun Shanghai Science And Technology Ltd | Liberación extendida de neurregulina para mejorar la función cardíaca |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| US20090156488A1 (en) * | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
| WO2009157919A1 (en) * | 2008-06-23 | 2009-12-30 | Tumor Biology Investment Group, Inc. | SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER |
| WO2010019952A2 (en) * | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
| EP2370458B1 (en) * | 2008-11-28 | 2014-10-15 | Zensun (Shanghai) Science and Technology Limited | Neuregulin peptides and their use |
| EP2370093A4 (en) * | 2008-11-28 | 2012-08-29 | Zensun Shanghai Science And Technology Ltd | NEUREGULIN AND CARDIAC STEM CELLS |
| EP2896632B1 (en) | 2009-11-13 | 2017-10-25 | Daiichi Sankyo Europe GmbH | Material and methods for treating or preventing HER-3 associated diseases |
| RS54795B1 (sr) | 2009-12-22 | 2016-10-31 | Roche Glycart Ag | Anti-her3 antitela i njihova korišćenja |
| KR101798679B1 (ko) | 2010-03-11 | 2017-11-16 | 메리맥 파마슈티컬즈, 인크. | ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도 |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| IT1402149B1 (it) * | 2010-10-04 | 2013-08-28 | Ist Fisioterap Ospitalroma | Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2. |
| ITRM20100577A1 (it) * | 2010-11-02 | 2012-05-03 | Takis Srl | Immunoterapia contro il recettore erbb-3 |
| TWI418362B (zh) * | 2010-11-19 | 2013-12-11 | Univ Nat Pingtung Sci & Tech | 溶血性巴斯德桿菌重組外膜脂蛋白e及含此之疫苗組成物 |
| US20140134170A1 (en) | 2011-03-11 | 2014-05-15 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
| MX2013010444A (es) | 2011-03-15 | 2014-03-21 | Merrimack Pharmaceuticals Inc | Superar la resistencia a inhibidores de la via erbb. |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| DK2797957T3 (da) | 2011-11-23 | 2019-09-23 | Medimmune Llc | Bindingsmolekyler specifikke for her3 og anvendelser deraf |
| WO2013110030A2 (en) * | 2012-01-19 | 2013-07-25 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
| CA2954279C (en) | 2014-07-07 | 2023-11-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| WO2016011343A1 (en) * | 2014-07-17 | 2016-01-21 | The Trustees Of The University Of Pennsylvania | Her3 peptides and dendritic cell vaccines |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| CA2992925A1 (en) * | 2015-07-17 | 2017-01-26 | The Trustees Of The University Of Pennsylvania | Identification of immunogenic mhc class ii peptides for immune-based therapy |
| WO2017040969A1 (en) | 2015-09-02 | 2017-03-09 | The Cleveland Clinic Foundation | Ovarian cancer vaccines |
| US11253580B2 (en) | 2016-01-07 | 2022-02-22 | Duke University | Cancer vaccines and methods of delivery |
| BR112019005001A2 (pt) * | 2016-09-15 | 2019-06-04 | Universität Stuttgart | proteína de ligação ao antígeno, proteína de fusão, ácido nucleico, vetor recombinante, célula hospedeira recombinante, composição farmacêutica, uso médico da proteína de ligação ao antígeno e método de inibição do crescimento tumoral |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| WO2019067673A1 (en) * | 2017-09-27 | 2019-04-04 | L2 Diagnostics, Llc | ERBB PEPTIDE-BASED PHARMACEUTICAL AND VACCINE COMPOSITIONS AND THEIR THERAPEUTIC USES FOR THE TREATMENT OF CANCER |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
| ES2166352T3 (es) | 1989-08-04 | 2002-04-16 | Schering Ag | Dominio externo de c-erbb-2:gp75. |
| US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5578482A (en) | 1990-05-25 | 1996-11-26 | Georgetown University | Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses |
| DE4221256C2 (de) | 1992-06-26 | 1997-07-10 | Lancaster Group Ag | Galenische Zusammensetzung für die topische Anwendung |
| US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| US5741511A (en) | 1995-04-12 | 1998-04-21 | Sam Yang Co., Ltd. | Transdermal drug delivery device for treating erectile dysfunction |
| US5888767A (en) | 1996-11-27 | 1999-03-30 | The Johns Hopkins University School Of Medicine | Method of using a conditionally replicating viral vector to express a gene |
| WO1997023256A1 (en) | 1995-12-22 | 1997-07-03 | Localmed, Inc. | Localized intravascular delivery of growth factors for promotion of angiogenesis |
| US5736154A (en) | 1996-03-11 | 1998-04-07 | Fuisz Technologies Ltd. | Transdermal delivery system |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| DE69736806T3 (de) | 1996-03-27 | 2015-10-08 | Genentech, Inc. | ErbB3 ANTIKÖRPER |
| CA2258721C (en) * | 1996-07-12 | 2014-09-09 | Genentech, Inc. | Chimeric heteromultimer adhesins |
| KR20060079258A (ko) | 1996-10-18 | 2006-07-05 | 제넨테크, 인크. | 항-ＥｒｂＢ２ 항체 |
| US5981201A (en) | 1997-01-08 | 1999-11-09 | Beth Israel Deaconess Medical Center | Methods of detection and treatment of breast cancer |
| US6387638B1 (en) | 1997-02-10 | 2002-05-14 | Genentech, Inc. | Heregulin variants |
| SE9703226D0 (sv) | 1997-09-08 | 1997-09-08 | Astra Ab | New pharmaceutical composition |
| US6197801B1 (en) | 1998-01-14 | 2001-03-06 | Usa Doctors Products, Inc. | Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
| US5962274A (en) | 1998-03-13 | 1999-10-05 | Wake Forest University | Viral vector directed to predetermined target cells |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| WO2001002600A2 (en) | 1999-07-06 | 2001-01-11 | General Atomics | Detection of analytes using attenuated enzymes |
| EA005931B1 (ru) | 2000-05-15 | 2005-08-25 | Фармация Италия С.П.А. | Ингибиторы ароматазы и моноклональные антитела против her2 как противоопухолевые агенты |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| CA2599606A1 (en) | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
-
2003
- 2003-03-26 AU AU2003218600A patent/AU2003218600C1/en not_active Ceased
- 2003-03-26 EP EP11178809.7A patent/EP2400021B1/en not_active Expired - Lifetime
- 2003-03-26 EP EP03711804.9A patent/EP1495123B1/en not_active Expired - Lifetime
- 2003-03-26 JP JP2003578561A patent/JP4660094B2/ja not_active Expired - Fee Related
- 2003-03-26 CN CNB038067625A patent/CN100424175C/zh not_active Expired - Fee Related
- 2003-03-26 WO PCT/CN2003/000217 patent/WO2003080835A1/en not_active Ceased
- 2003-03-26 CA CA2480099A patent/CA2480099C/en not_active Expired - Fee Related
- 2003-03-26 US US10/516,759 patent/US7919098B2/en not_active Expired - Lifetime
-
2010
- 2010-04-26 JP JP2010101148A patent/JP5249282B2/ja not_active Expired - Lifetime
-
2011
- 2011-02-25 US US13/035,244 patent/US20110229478A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010213710A5 (enExample) | ||
| TWI868726B (zh) | 抗體-藥物結合物之新穎製造方法 | |
| AU2024264558A1 (en) | Bicyclic peptide ligands specific for Nectin-4 | |
| TWI712423B (zh) | 抗ｔｒｏｐ２抗體-藥物結合物之製造方法 | |
| ES2717911T3 (es) | Combinaciones farmacéuticas que comprenden un inhibidor de B-Raf, un inhibidor de EGFR y opcionalmente un inhibidor de PI3K-alfa | |
| JP2014526462A5 (enExample) | ||
| JP2011130770A5 (enExample) | ||
| JP2010110329A5 (enExample) | ||
| JP2013513559A5 (enExample) | ||
| JP2012509259A5 (enExample) | ||
| JP2018522822A5 (enExample) | ||
| JP2010531140A5 (enExample) | ||
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| JP2018502120A5 (enExample) | ||
| RU2014151207A (ru) | Селективность в отношении мутантных форм и комбинации соединения, представляющего собой ингибитор фосфоинозитид-3-киназы, и химиотерапевтических агентов для лечения рака | |
| RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
| JP2014508782A5 (enExample) | ||
| JP2010529026A5 (enExample) | ||
| ITRM20100577A1 (it) | Immunoterapia contro il recettore erbb-3 | |
| JP2014500862A5 (enExample) | ||
| US20170202902A1 (en) | Conjugates for immunotherapy | |
| JP2018532715A5 (enExample) | ||
| WO2023061457A1 (zh) | 抗体药物偶联物及其用途 | |
| JP2015517523A5 (enExample) | ||
| JP2021054851A (ja) | 逐次的抗癌治療 |